- Home
- ACIU vs MQT Comparison
ACIU vs MQT Comparison
Compare ACIU & MQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- MQT
- Stock Information
- Founded
- ACIU 2003
- MQT 1992
- Country
- ACIU Switzerland
- MQT United States
- Employees
- ACIU N/A
- MQT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- MQT Investment Bankers/Brokers/Service
- Sector
- ACIU Health Care
- MQT Finance
- Exchange
- ACIU Nasdaq
- MQT Nasdaq
- Market Cap
- ACIU 189.1M
- MQT 210.8M
- IPO Year
- ACIU 2016
- MQT N/A
- Fundamental
- Price
- ACIU $2.02
- MQT $9.58
- Analyst Decision
- ACIU Strong Buy
- MQT
- Analyst Count
- ACIU 1
- MQT 0
- Target Price
- ACIU $12.00
- MQT N/A
- AVG Volume (30 Days)
- ACIU 128.8K
- MQT 52.5K
- Earning Date
- ACIU 08-05-2025
- MQT 01-01-0001
- Dividend Yield
- ACIU N/A
- MQT 4.60%
- EPS Growth
- ACIU N/A
- MQT N/A
- EPS
- ACIU N/A
- MQT N/A
- Revenue
- ACIU $32,014,254.00
- MQT N/A
- Revenue This Year
- ACIU N/A
- MQT N/A
- Revenue Next Year
- ACIU $533.21
- MQT N/A
- P/E Ratio
- ACIU N/A
- MQT N/A
- Revenue Growth
- ACIU 91.20
- MQT N/A
- 52 Week Low
- ACIU $1.43
- MQT $8.59
- 52 Week High
- ACIU $4.26
- MQT $10.67
- Technical
- Relative Strength Index (RSI)
- ACIU 57.93
- MQT 45.31
- Support Level
- ACIU $2.01
- MQT $9.50
- Resistance Level
- ACIU $2.19
- MQT $9.58
- Average True Range (ATR)
- ACIU 0.14
- MQT 0.06
- MACD
- ACIU 0.00
- MQT 0.01
- Stochastic Oscillator
- ACIU 60.75
- MQT 64.29
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.